AR075908A1 - PHARMACEUTICAL FORMULATION CONTAINING IMPROVED ANTIBODY MOLECULES, POLYPEPTIDES. METHOD FOR STABILIZING SOLUTION, ANTIBODY. - Google Patents

PHARMACEUTICAL FORMULATION CONTAINING IMPROVED ANTIBODY MOLECULES, POLYPEPTIDES. METHOD FOR STABILIZING SOLUTION, ANTIBODY.

Info

Publication number
AR075908A1
AR075908A1 ARP100100904A ARP100100904A AR075908A1 AR 075908 A1 AR075908 A1 AR 075908A1 AR P100100904 A ARP100100904 A AR P100100904A AR P100100904 A ARP100100904 A AR P100100904A AR 075908 A1 AR075908 A1 AR 075908A1
Authority
AR
Argentina
Prior art keywords
seq
sequence
cdr1
cdr2
cdr3
Prior art date
Application number
ARP100100904A
Other languages
Spanish (es)
Inventor
Mika Sakurai
Tetsuo Kojima
Hiroyuki Tsunoda
Tatsuhiko Tachibana
Atsuhiko Maeda
Yoshinobu Higuchi
Hirotake Shiraiwa
Tomoyuki Igawa
Shinya Ishii
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR075908A1 publication Critical patent/AR075908A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Reivindicacion 1: Una formulacion farmacéutica, caracterizada porque comprende al menos un polipéptido seleccionado entre: (a) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:1 (CDR1 de VH4-M73), una CDR2 que comprende la secuencia de la SEQ ID N°:2 (CDR2 de VH4-M73) y una CDR3 que comprende la secuencia de la SEQ ID N°:3 (CDR3 de VH4-M73); (b) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:4 (CDR1 de VH3-M73), una CDR2 que comprende la secuencia de la SEQ ID N°:5 (CDR2 de VH3-M73) y una CDR3 que comprende la secuencia de la SEQ ID N°:6 (CDR3 de VH3-M73); (c) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:7 (CDR1 de VH5-M83), una CDR2 que comprende la secuencia de la SEQ ID N°:8 (CDR2 de VH5-M83) y una CDR3 que comprende la secuencia de la SEQ ID N°:9 (CDR3 de VH5-M83); (d) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:10 (CDR1 de VL1), una CDR2 que comprende la secuencia de la SEQ ID N°:11 (CDR2 de VL1) y una CDR3 que comprende la secuencia de la SEQ ID N°:12 (CDR3 de VL1); e) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:13 (CDR1 de VL3), una CDR2 que comprende la secuencia de la SEQ ID N°:14 (CDR2 de VL3) y una CDR3 que comprende la secuencia de la SEQ ID N°:15 (CDR3 de VL3); y (f) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:16 (CDR1 de VL5), una CDR2 que comprende la secuencia de la SEQ ID N°:17 (CDR2 de VL5) y una CDR3 que comprende la secuencia de la SEQ ID N°:18 (CDR3 de VL5). Reivindicacion 5: Una formulacion farmacéutica estable de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizada porque comprende 1-500 mM de agente amortiguador de histidina y/o citrato, 1-1500 mM de al menos un aminoácido cationico, 1-200 mg/mL de anticuerpo, y 1-400 mM de un carbohidrato. Reivindicacion 12: La formulacion de acuerdo con cualquiera de las reivindicaciones 1 a 11, caracterizada porque contiene el polipéptido y/o anticuerpo en una cantidad inferior o igual a 240 mg/ml. Reivindicacion 15: La formulacion de acuerdo con cualquiera de las reivindicaciones 1 a 14, caracterizada porque la formulacion es líquida. Reivindicacion 16: La formulacion de acuerdo con la reivindicacion 15, caracterizada porque no se sometio a liofilizacion durante la preparacion de la misma.Claim 1: A pharmaceutical formulation, characterized in that it comprises at least one polypeptide selected from: (a) a polypeptide comprising a CDR1 comprising the sequence of SEQ ID N °: 1 (CDR1 of VH4-M73), a CDR2 comprising the sequence of SEQ ID N °: 2 (CDR2 of VH4-M73) and a CDR3 comprising the sequence of SEQ ID N °: 3 (CDR3 of VH4-M73); (b) a polypeptide comprising a CDR1 comprising the sequence of SEQ ID N °: 4 (CDR1 of VH3-M73), a CDR2 comprising the sequence of SEQ ID N °: 5 (CDR2 of VH3-M73) and a CDR3 comprising the sequence of SEQ ID N °: 6 (CDR3 of VH3-M73); (c) a polypeptide comprising a CDR1 comprising the sequence of SEQ ID N °: 7 (CDR1 of VH5-M83), a CDR2 comprising the sequence of SEQ ID N °: 8 (CDR2 of VH5-M83) and a CDR3 comprising the sequence of SEQ ID N °: 9 (CDR3 of VH5-M83); (d) a polypeptide comprising a CDR1 comprising the sequence of SEQ ID N °: 10 (CDR1 of VL1), a CDR2 comprising the sequence of SEQ ID N °: 11 (CDR2 of VL1) and a CDR3 which comprises the sequence of SEQ ID N °: 12 (CDR3 of VL1); e) a polypeptide comprising a CDR1 comprising the sequence of SEQ ID N °: 13 (CDR1 of VL3), a CDR2 comprising the sequence of SEQ ID N °: 14 (CDR2 of VL3) and a CDR3 comprising the sequence of SEQ ID N °: 15 (CDR3 of VL3); and (f) a polypeptide comprising a CDR1 comprising the sequence of SEQ ID N °: 16 (CDR1 of VL5), a CDR2 comprising the sequence of SEQ ID N °: 17 (CDR2 of VL5) and a CDR3 comprising the sequence of SEQ ID N °: 18 (CDR3 of VL5). Claim 5: A stable pharmaceutical formulation according to any one of claims 1 to 4, characterized in that it comprises 1-500 mM of histidine and / or citrate buffering agent, 1-1500 mM of at least one cationic amino acid, 1-200 mg / mL of antibody, and 1-400 mM of a carbohydrate. Claim 12: The formulation according to any one of claims 1 to 11, characterized in that it contains the polypeptide and / or antibody in an amount less than or equal to 240 mg / ml. Claim 15: The formulation according to any of claims 1 to 14, characterized in that the formulation is liquid. Claim 16: The formulation according to claim 15, characterized in that it was not subjected to lyophilization during the preparation thereof.

ARP100100904A 2009-03-19 2010-03-19 PHARMACEUTICAL FORMULATION CONTAINING IMPROVED ANTIBODY MOLECULES, POLYPEPTIDES. METHOD FOR STABILIZING SOLUTION, ANTIBODY. AR075908A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009069095 2009-03-19

Publications (1)

Publication Number Publication Date
AR075908A1 true AR075908A1 (en) 2011-05-04

Family

ID=42739479

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100904A AR075908A1 (en) 2009-03-19 2010-03-19 PHARMACEUTICAL FORMULATION CONTAINING IMPROVED ANTIBODY MOLECULES, POLYPEPTIDES. METHOD FOR STABILIZING SOLUTION, ANTIBODY.

Country Status (8)

Country Link
JP (2) JP4885308B2 (en)
KR (1) KR101468271B1 (en)
AR (1) AR075908A1 (en)
AU (1) AU2010225951B2 (en)
RU (1) RU2565809C2 (en)
SG (3) SG10201703707YA (en)
TW (1) TWI440470B (en)
WO (1) WO2010106812A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
JP5334319B2 (en) 2007-09-26 2013-11-06 中外製薬株式会社 Method for modifying isoelectric point of antibody by amino acid substitution of CDR
PL2708558T3 (en) 2008-04-11 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd FORMULATIONS STABILIZED LIQUID CONTAINERS OF ANTIBODIES
CN105218674A (en) 2010-03-11 2016-01-06 瑞纳神经科学公司 The antibody combined in pH dependence antigen
KR20220070586A (en) * 2010-11-08 2022-05-31 제넨테크, 인크. Subcutaneously administered anti-il-6 receptor antibody
WO2012073992A1 (en) 2010-11-30 2012-06-07 中外製薬株式会社 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
WO2012132067A1 (en) * 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
CA2827923C (en) * 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
JP6124800B2 (en) 2011-11-30 2017-05-10 中外製薬株式会社 Medicament containing carrier (carrier) into cells forming immune complex
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EP3082861A1 (en) * 2013-12-20 2016-10-26 DioGenix Inc. Methods for evaluating neurological disease
KR102344170B1 (en) 2013-12-27 2021-12-27 추가이 세이야쿠 가부시키가이샤 Method for purifying antibody having low isoelectric point
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
CA2986210C (en) * 2015-05-22 2022-04-26 Astellas Pharma Inc. Novel anti-human ngf antibody fab fragment
EP3391904A4 (en) 2015-12-18 2019-09-25 Astellas Pharma Inc. Pharmaceutical composition containing anti-human tslp receptor antibody
US10961314B2 (en) * 2016-09-27 2021-03-30 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody
EP3589318A1 (en) * 2017-03-01 2020-01-08 MedImmune Limited Formulations of monoclonal antibodies
JP7185884B2 (en) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE
KR20200074160A (en) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody
JP2021504482A (en) * 2017-11-30 2021-02-15 バイオ−テラ ソリュ−ションズ，エルティーディー． Liquid formulation of humanized antibody for the treatment of IL-6 related diseases
TWI822728B (en) 2018-01-31 2023-11-21 加藤元一 Asthma therapeutic agents containing IL-6 inhibitors
WO2020047029A1 (en) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
MX2021009242A (en) 2019-01-31 2021-10-26 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis.
US20220220210A1 (en) 2019-03-29 2022-07-14 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
JPWO2020213665A1 (en) 2019-04-17 2020-10-22
CN115697404A (en) 2020-05-29 2023-02-03 中外制药株式会社 Antibody-containing preparation
KR20220028972A (en) * 2020-08-31 2022-03-08 (주)셀트리온 Stable Pharmaceutical Formulation
KR20230156368A (en) 2021-03-12 2023-11-14 추가이 세이야쿠 가부시키가이샤 Pharmaceutical composition for the treatment or prevention of myasthenia gravis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1060194A1 (en) * 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
PT2308888T (en) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anti-il-6 antibodies, compositions, methods and uses
EP1475101B1 (en) * 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
JP4768439B2 (en) * 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
JP4685764B2 (en) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
JP2008505054A (en) * 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Methods of treating osteoarthritis with IL-6 antagonists
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
EP1988922A4 (en) * 2006-02-03 2010-06-02 Medimmune Llc Protein formulations
WO2007114319A1 (en) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
ATE537190T1 (en) * 2006-06-02 2011-12-15 Regeneron Pharma HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR
JP5334319B2 (en) * 2007-09-26 2013-11-06 中外製薬株式会社 Method for modifying isoelectric point of antibody by amino acid substitution of CDR
TWI464262B (en) * 2007-09-26 2014-12-11 中外製藥股份有限公司 Antibody constant region mutant
AU2008304756B8 (en) * 2007-09-26 2015-02-12 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 receptor antibody
PL2708558T3 (en) * 2008-04-11 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Also Published As

Publication number Publication date
WO2010106812A1 (en) 2010-09-23
KR20110139745A (en) 2011-12-29
JP2011173918A (en) 2011-09-08
AU2010225951A1 (en) 2011-09-22
TWI440470B (en) 2014-06-11
AU2010225951B2 (en) 2014-03-13
RU2011142184A (en) 2013-04-27
KR101468271B1 (en) 2014-12-03
SG10201900451SA (en) 2019-02-27
RU2565809C2 (en) 2015-10-20
JP4885308B2 (en) 2012-02-29
TW201100100A (en) 2011-01-01
JP2012504106A (en) 2012-02-16
SG10201703707YA (en) 2017-06-29
SG174428A1 (en) 2011-10-28
JP5661553B2 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
AR075908A1 (en) PHARMACEUTICAL FORMULATION CONTAINING IMPROVED ANTIBODY MOLECULES, POLYPEPTIDES. METHOD FOR STABILIZING SOLUTION, ANTIBODY.
CY1123657T1 (en) STABLE PHARMACEUTICAL FORM OF ANTI-IFNAR1
EA200970880A1 (en) STABLE COMPOSITIONS BASED ON ANTIBODIES
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
NZ719036A (en) Anti-pdl1 antibody formulations
MX2019003716A (en) Pharmaceutical formulations of tnf-alpha antibodies.
Teng et al. An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes
PE20141727A1 (en) COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES
BR112012022223A2 (en) concentrated protein formulations and uses thereof
HRP20120903T1 (en) High concentration antibody-containing liquid formulation
EA201590525A1 (en) SLIP PROTEINS FOR THE TREATMENT OF METABOLIC SYNDROME
PH12014501628B1 (en) Stabilized formulations containing anti-ang2 antibodies
PE20091193A1 (en) HUMAN ANTIGEN BINDING PROTEINS FROM GM-CSF
MX2014001372A (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
ECSP099403A (en) PARENTERAL FORMULATION OF ABET ANTIBODY
MX361668B (en) Antibody formulation.
BR112016026811A2 (en) antibody formulation
PE20190733A1 (en) ANTIBODIES AGAINST DENGUE VIRUS, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS, AND METHODS OF USE
EA201992570A1 (en) COMPOSITIONS BASED ON HUMAN ANTIBODIES TO RANKL, AND ALSO WAYS OF THEIR APPLICATION
BR112016014913A8 (en) antibody, or an antigen-binding fragment thereof, conjugate, nucleic acid, vector, host cell, pharmaceutical composition, method of preparing an antibody light chain or antigen-binding fragment, and method of preparing a conjugate
NZ702342A (en) Pharmaceutical formulation
MX2013007146A (en) Oprf/i agents and their use in hospitalized and other patients.
AR117607A1 (en) HIGH CONCENTRATION LIQUID ANTIBODY FORMULATIONS
MX2021011137A (en) Stabilized formulations containing anti-il-33 antibodies.
UY32600A (en) FORMULATION IN LIPIDS OF AN APOPTOSIS PROMOTER

Legal Events

Date Code Title Description
FB Suspension of granting procedure